Skip to main content

Advertisement

Springer Nature Link
Log in

8p21.3 deletion suggesting a probable role of TRAIL-R1 and TRAIL-R2 as candidate tumor suppressor genes in the pathogenesis of multiple myeloma

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

8p21.3 deletion was recently characterized in B cell lymphoma suggesting that TRAIL-R1 and TRAIL-R2 may be the target of the deletion and act as dosage-dependent tumor suppressor genes. As multiple myeloma is a plasma cell malignancy originating from B-lineage clonogenic cells, the idea was why do not evaluate this deletion in this pathology. Thus, interphase FISH studies with two mixtures of probes spanning the 8p21.3 region were retrospectively performed in 37 French multiple myeloma patients. Surprisingly, deletion in this region was found in 8 (21.6 %) patients. Interestingly, this deletion was usually associated with a 13q14 deletion. In two among them, the patients showed also translocation (4;14)(p16;q32) and one other harbor also a deletion of the P53 gene. These results indicate that deletion of TRAIL-R1 and TRAIL-R2 may be relevant to the loss of 8p21.3 and may play an important role the pathogenesis of MM. The association of this deletion with other well-known chromosomal aberrations in multiple myeloma suggests, as previously described, that these anomalies are not randomly distributed, but strongly interconnected.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Explore related subjects

Discover the latest articles and news from researchers in related subjects, suggested using machine learning.

References

  1. Kyle RA, Rajkumar SV. Plasma cell disorders. In: Goldman L, Ausiello DA, editors. Cecil textbook of medicine. 22nd ed. Philadelphia, PA: W.B. Saunders; 2004. p. 1184–95.

    Google Scholar 

  2. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, Leyvraz S, Michallet M, Yakoub-Agha I, Garderet L, Marit G, Michaux L, Voillat L, Renaud M, Grosbois B, Guillerm G, Benboubker L, Monconduit M, Thieblemont C, Casassus P, Caillot D, Stoppa AM, Sotto JJ, Wetterwald M, Dumonte C, Fuzibet JG, Azais I, Dorvaux V, Zandecki M, Bataille R, Minvielle S, Harousseau JL, Facon T, Mathiot C. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood. 2007;109:3489–95.

    Article  PubMed  CAS  Google Scholar 

  3. Rubio-Moscardo F, David B, Mestre C, Siebert R, Balasas T, Benito A, Rosenwald A, Climent J, Martinez JI, Schilhabel M, Lorraine Karran E, Gesk S, Esteller M, deLeeuw R, Staudt LM, Fernandez-Luna JL, Pinkel D, Dyer MJS, Martinez-Climent JA. Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes. Blood. 2006;106:3214–22.

    Article  Google Scholar 

  4. Avet-Loiseau H, Facon T, Daviet A, Godon C, Rapp MJ, Harousseau JL, Grosbois B, Bataille R. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Cancer Res. 1999;59:4546–50.

    PubMed  CAS  Google Scholar 

  5. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting—Airlie House, Virginia, November, 1997. Hematol J. 2000;1:53–66.

    Article  PubMed  CAS  Google Scholar 

  6. McDonnell TJ, Korsmeyer SJ. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18). Nature. 1991;349:254–6.

    Article  PubMed  CAS  Google Scholar 

  7. Lovec H, Grzeschiczek A, Kowalski MB, Moroy T. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J. 1994;13:3487–95.

    PubMed  CAS  Google Scholar 

  8. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996;271:12687–90.

    Article  PubMed  CAS  Google Scholar 

  9. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673–82.

    Article  PubMed  CAS  Google Scholar 

  10. Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Yagita H, Okumura K. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med. 2002;195:161–9.

    Article  PubMed  CAS  Google Scholar 

  11. Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Yamaguchi N, Yagita H, Okumura K. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-γ-dependent suppression of subcutaneous tumor growth. Cell Immunol. 2001;214:194–200.

    Article  PubMed  CAS  Google Scholar 

  12. Frank S, Kohler U, Schackert G, Schackert HK. Expression of TRAIL and its receptors in human brain tumors. Biochem Biophys Res Commun. 1999;257:454–9.

    Article  PubMed  CAS  Google Scholar 

  13. Daniels RA, Turley H, Kimberley FC, Liu XS, Mogkolsapaya J, Ch’en P, Xu XN, Jin B, Pezzella F, Gavin R, Screaton GR. Expression of TRAIL and TRAIL receptors in normal and malignant tissues. Cell Res. 2005;15:430–8.

    Article  PubMed  CAS  Google Scholar 

  14. Ryu B, Song J, Sohn T, Ralph H, Hruban RH, Scott E, Kern SE. Frequent germline deletion polymorphism of chromosomal region 8p12–p21 identified as a recurrent homozygous deletion in human tumors. Genomics. 2001;72:108–12.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We are grateful to all the team of the Hematology Department, University Hospital Hôtel Dieu, Nantes, France and special thanks to Nadège Gouy, Audrey Ruau, Amandine Gaudet, Marine Aliaga, Cyrille Pierre.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Cytogenetics and Reproductive Biology, Farhat Hached University Hospital, Sousse, Tunisia

    A. Gmidène & A. Saad

  2. Hematology Laboratory, INSERM U463, and the Department of Clinical Hematology, University Hospital, Nantes, France

    A. Gmidène & H. Avet-Loiseau

Authors
  1. A. Gmidène
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. A. Saad
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. H. Avet-Loiseau
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to A. Gmidène.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gmidène, A., Saad, A. & Avet-Loiseau, H. 8p21.3 deletion suggesting a probable role of TRAIL-R1 and TRAIL-R2 as candidate tumor suppressor genes in the pathogenesis of multiple myeloma. Med Oncol 30, 489 (2013). https://doi.org/10.1007/s12032-013-0489-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-013-0489-8

Keywords